* Guilford Pharmaceuticals Inc., of Baltimore, said it gained exclusive worldwide rights to a patent covering delivery of cancer chemotherapeutics in biodegradable polymers for treatment of solid tumors. The patents were licensed from Johns Hopkins University in Baltimore and the Massachusetts Institute of Technology in Cambridge, Mass. Financial terms were not disclosed.
* SangStat Medical Corp., of Menlo Park, initiated pivotal bioequivalence trials with its version of cyclosporine, an immunosuppressive drug used to prevent organ transplant rejections. The trials will support the company's FDA application for a generic drug approval. The product currently is marketed by Sandoz Ltd., of Basel, Switzerland.
* Synteni Inc., of Palo Alto, Calif., entered a collaboration with Hoffmann-La Roche Inc., of Nutley, N.J., to supply the pharmaceutical company with gene expression information. Financial terms were not disclosed. Hoffmann-La Roche, a subsidiary of Basel, Switzerland-based Roche Holding Ltd., will use Synteni's Gene Expression Micro-array technology to analyze expression levels of thousands of genes.
* The Liposome Co., of Princeton, N.J., said its board adopted a shareholder rights plan to discourage any person or group from acquiring more than 15 percent of the company's stock. The company said the move was not made in response to any takeover attempt.
* Vertex Laboratories Inc., of Englewood, Calif., said its controlled- release AZT formulation, Aztec, resulted in significantly reduced side effects compared to AZT. Also, only one of 72 Aztec patients developed resistance compared to 10 of 76 AZT patients.
(c) 1997 American Health Consultants. All rights reserved.